MIM
SPRO icon

MetLife Investment Management’s Spero Therapeutics SPRO Stock Holding History

MetLife Investment Management’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-9,977
Closed -$160K – 2768
2021
Q4 		$160K Hold
9,977
– – ﹤0.01% 2193
2021
Q3 		$184K Hold
9,977
– – ﹤0.01% 2152
2021
Q2 		$139K Buy
9,977
+7,949
+392% +$111K ﹤0.01% 2356
2021
Q1 		$29.9K Sell
2,028
-7,402
-78% -$130K ﹤0.01% 2295
2020
Q4 		$183K Buy
+9,430
New +$147K ﹤0.01% 2028
2020
Q3 		– Sell
-7,571
Closed -$102K – 2331
2020
Q2 		$102K Buy
+7,571
New +$85K ﹤0.01% 2246

Other funds holding SPRO

ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

MetLife Investment Management's SPRO Position: Q1 2022 in Review

MetLife Investment Management sold out of Spero Therapeutics (SPRO) in Q1 2022, closing a stake of 9,977 shares — an estimated $160K sold.

MetLife Investment Management first reported a position in SPRO in Q2 2020 and held it in 6 quarters. The position peaked at $184K in Q3 2021. 100 funds tracked by Wall St. Rank hold SPRO as of Q1 2022.

  • MetLife Investment Management reported no remaining Spero Therapeutics position as of Q1 2022 after selling out during the quarter.
  • MetLife Investment Management sold 9,977 Spero Therapeutics shares in Q1 2022, an estimated $160K.
  • MetLife Investment Management first reported a position in Spero Therapeutics in Q2 2020 and held it in 6 quarters.
  • MetLife Investment Management's Spero Therapeutics position peaked at $184K in Q3 2021.
  • 100 funds tracked by Wall St. Rank held Spero Therapeutics as of Q1 2022.

Based on MetLife Investment Management's 13F filing for Q1 2022, filed 12 May 2022.